Recommendations regarding the use of plant-derived medications for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) state that every brand should be fully evaluated and considered separately. Disparity between a number of brands in terms of their stated and actual doses has been recently highlighted. The aim of this study was to fully quantify the variation in Serenoa repens extracts (SrE) commercially available for the treatment of BPH-associated LUTS. To this end, 14 brands of SrE were compared. Concentrations of free fatty acids (FFAs), methyl and ethyl esters, longchain esters and glycerides were assessed using liquid and gas chromatography. Many of the brands showed a significantly different proportional content which may have an impact on their clinical efficacy and safety. The high concentrations of FFAs in particular, which previous research has suggested as comprising the active agent of SrE for the treatment of LUTS, may influence the clinical benefit derived from each product. Our findings lend further weight to recommendations by the 5th International Consultation on BPH that plant-derived treatments should be analysed and considered as independent entities despite their common origin. Only extracts with demonstrated pharmacological activities and proven clinical efficacy should be considered for the treatment of patients with BPH.
Introduction
Medical therapies derived from natural sources have been in use for centuries. In addition to traditional, commercially available remedies for the treatment of, for example, cardiovascular disease (Achillea millefolium), depression (Hypericum perforatum, St. John's wort) and constipation (Cassia acutifolia, Senna), use of plantderived medication requiring prescription is also widespread. Docetaxel and paclitaxel, derived from the needles of the English and Pacific yew, respectively, and vinca alkaloids, such as vinblastine and vinorelbine, derived from the periwinkle, are widely used in the treatment of cancer and are recognised for being as effective as synthetically based medications. In the majority of European Union member states, such products are not distinguished from chemically derived medicinal products. 1 Future plant-derived pharmaceuticals may include derivatives of Artemisia annua (wormwood) for the prophylaxis or treatment of malaria 2 and Bupleurum species for hepatitis B. 3 The use of plant-derived medication is increasing in many therapeutic areas, and conditions of the prostate are no exception. This is partially driven by the increasing prevalence of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), 4 and from an increased awareness of the benefits of such types of therapy. 5 In particular, extracts of the American dwarf palm (Serenoa repens, saw palmetto) and blends containing this compound are extremely common treatments for LUTS and are widely available throughout Europe and the USA. 6 Around half of all BPH treatments dispensed in Italy comprise phytotherapeutic agents, and in Austria and Germany such treatments represent over 90% of all BPH drugs dispensed. 7, 8 Their use is also rising in the USA, where one-third of men opting for non-surgical treatment report taking phytotherapy. 9 The underlying basis for the popularity of S. repens extracts (SrE) includes its safety and tolerability profile; there is, in fact, a remarkably benign side-effect profile and the product is virtually free of the deleterious effects on sexual function 10, 11 that are commonly observed with many BPH treatments, such as the a-blocker tamsulosin and the 5a-reductase inhibitor finasteride. Long-term use of SrE has shown no increase in adverse effects over time. 12 Despite being widely used for many years, particularly in Europe, the mechanism of action of SrE has not been definitively clarified. Although in vitro studies have shown the compound to be a non-competitive inhibitor of 5a-reductase, 13 it has also been suggested that it has anti-oestrogenic, anti-inflammatory and proapoptotic effects. [14] [15] [16] Definitive in vivo studies attributing the clinical benefits derived from SrE to any particular component are lacking; however, research has suggested that the active agents of the compound mainly comprise free fatty acids (FFAs), particularly lauric, oleic, myristic and palmitic acids. 17, 18 It has been suggested that other elements may also contribute to its action. The unsaponifiable element of Permixon, for example, has been found to reduce prostate cell proliferation in response to stimulation by basic fibroblast growth factor. 14 Other elements may also be involved in the clinical benefits resulting from SrE, including flavonoids and sterols. These have been shown to inhibit cyclo-oxygenase and lipoxygenase pathways and may also exert anti-inflammatory effects. 19, 20 However, further investigation is required to establish the role of these components in the clinical efficacy of SrE.
Not surprisingly perhaps, it has been suggested that if the content of different brands of SrE differs significantly, there will be a corresponding impact on both biological and clinical activity. Clinical efficacy may be compromised if the active elements of a medication are present in far higher or lower concentrations than indicated. In addition, patient and doctor perception of the reliability of a particular product may be influenced by such discrepancies.
The majority of SrE brands have undergone little or no formal clinical or pharmacological analysis and so no definitive statements regarding their global benefit-risk profiles can be made. Individually, however, some extracts have demonstrated clinical efficacy. The clinical value of Permixon, a lipido-sterolic extract commercialised by Pierre Fabre Médicament, has been shown in several large-scale clinical trials in recent years [21] [22] [23] and in meta-analyses of all clinical trial data. 24, 25 The latest of these meta-analyses indicated reduced episodes or nocturia, increased peak flow and improvements in International Prostate Symptom Score (IPSS). Such improvements in IPSS have been found to accompany rises in quality of life measures, while prostate specific antigen and sexual function remain unchanged. 12, 22, 23 It is possible that other SrE, may be as effective, but the shortage of adequate, well-controlled trials of other extracts renders comparison difficult, if not impossible.
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These observations, coupled with the documented variation between products, led the 5th International Consultation on BPH to recommend that even products derived from the same source be submitted to separate and rigorous evaluation in both clinical and pharmacological trials. 26 In order to determine the proportional content of the different types of SrE, a comparison of the principle components of the most commonly used medicinal SrE, was carried out.
Materials and methods
A total of 14 brands that either require a prescription or are commercially available in Europe were compared, including Permixon (Pierre Fabre Médicament, Castres, France), Prostagutt uno (Willmar Schwabe, Karlsruhe, Germany), Prostamol uno (Berlin-Chemie, Berlin, Germany), Prosta-urgenine (Hoyer-Madaus, Mannheim, Germany), Prosteren (Sirton Pharmaceuticals, Villaguardia, Italy), Prostess (TAD Pharmazeutisches Werk, Cuxhaven, Germany), Quanterra prostate (Warner-Lambert, Morris Plains, NJ, USA), Ratiopharm uno (Ratiopharm, Ulm, Germany), Rilaprost (Guidotti, San Piero a Grado, Italy), Saba (Lampugnani, Milan, Italy), Sita (Hoyer-Madaus, Mannheim, Germany), Strogen uno (Strathmann, Hamburg, Germany), Solaray (Nutraceutical Corporation, Park City, UT, USA) and Talso uno (Sanofi Winthrop, Morrisville, PA, USA).
The fractions of the different products were first extracted using standardised methods (Figure 1 ). The different SrE were initially subjected to preparatory chromatography on aminopropyl silica using chloroform and isopropanol in a 2 : 1 ratio and ether and formic acid in a 98 : 2 ratio to separate the FFA portion from the esters.
The methyl and ethyl esters, long-chain esters and glycerides (P1) were then quantified by weight while, the FFAs (caproic, caprylic, capric, lauric, myristic, palmitic, palmitoleic, stearic, oleic, linoleic, linolenic, arachidic and eicosenoic acids) were quantified by gas chromatography. Separation of the ester and glyceride fractions then took place using preparatory chromatography on high-purity silica with a 2% water content using hexane and ether in a ratio of 99 : 1.
The methyl and ethyl ester element and the long-chain ester element were then quantified by weight (P2) and noneluted quantification of the glycerides by weight was also carried out by subtracting the weight of P2 from P1. Gas chromatography then took place in order to quantify the methyl and ethyl ester and long-chain ester fractions.
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The unsaponifiable matter, comprising the diethyl ether extraction after saponification of the product with concentrated potassium hydroxide, was also quantified by weight. Defined internal standards of FFA, methyl esters, longchain esters and glycerides dictated that the carbon chain length of quantifiable FFAs was C13 and C17, that of quantifiable methyl and ethyl esters was C11 and C17, that of quantifiable long-chain esters was C34 and that of quantifiable glycerides was C45.
Capillary columns were used in the gas chromatography analysis of each fraction, with BPX21 (FFAP) injected into the column of the FFA fraction, BPX20 (Carbowax 20 M) injected in a splitless fashion on the methyl and ethyl ester fraction and BD1 (silicone) injected into the column of the long-chain ester (which included esters from fatty acids with fatty alcohols or sterols) and into the glyceride fraction.
Results
The analyses of all 14 products revealed marked differences between brands, despite their common origin ( Table 1 ). The mean proportion of FFAs ranged from 80.7% in Permixon to 40.7% in Solaray (which is known to contain 50% olive oil and is marketed as such) and 54.05% in Prosta-urgenine, indicating an extremely wide variety of dosages of this fraction.
Each of the individual FFAs analysed was found in similar proportions in all the products assayed, with lauric and oleic acids present at the highest concentrations in every sample assayed.
Methyl and ethyl ester content ranged from 16.7% Prosta-urgenine to 1.5% in Solaray, while long-chain ester content ranged from 1.36% in Permixon to 0.7% in Prosta-urgenine.
Glyceride content was highest in Solaray, at 52.15%, and lowest in Permixon, at 6.8%, while unsaponifiable matter concentrations ranged from 2.6% in Prostess to 1.6% in both Ratiopharm uno and Solaray. Significantly higher concentrations of glycerides were observed in all brands compared to Permixon, while similar concentrations of methyl and ethyl esters were found in Prosteren, Saba, Rilaprost, Permixon and Solaray (Figure 2) .
The methyl and ethyl ester content was particularly high (at around 10-15%) in the Prostagutt uno, Prostaurgenine, Prostamol uno, Prostess and Sita products. Glyceride content was particularly high (420%) in Saba, Rilaprost, Sita, Ratiopharm uno, Quanterra prostate, Talso uno, Prostamol uno, Prostagutt uno, Strogen uno and Solaray (Figure 2) .
In general similar content composition was observed between Saba and Rilaprost, between Prostagutt uno,
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Chromatography Figure 1 Extraction of the Serenoa repens fractions. Preparatory chromatography separated the free fatty acids from the esters/glycerides, which were quantified by gas chromatography and weight (P1), respectively. The ester and glyceride fractions were separated using preparatory chromatography, and the methyl and ethyl esters and the long-chain esters were then quantified by weight (P2). P1-P2 gave the noneluted quantification of the glycerides. Gas chromatography quantified the methyl and ethyl esters and long-chain ester fractions. The unsaponifiable matter was weight quantified.
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Strogen uno and Talso uno and also between Sita and Prostess.
Discussion
Significant differences in SrE were observed in the 14 brands analysed. The disparity between the extracts indicates that the clinical benefits derived will vary between products, and this may also impact on patients transferring from one brand to another. However, it is possible that the differences observed in our study were linked to variations in the methods of extraction. There is also the possibility that clinical benefit is derived from another component not analysed here (eg phyto-oestrogens), however, the FFA content of SrE has generally been regarded as the source of the clinical benefits, together with a small contribution from unsaponifiable components of SrE. 14 Although a minimum FFA dose necessary for clinical efficacy has not yet been defined, higher concentrations of FFAs may be expected to be associated with greater improvements in clinical symptoms.
The recommendation of the 5th International Consultation on BPH that products with a similar source be evaluated separately suggests that there is a widely held belief that great variation exists between different commercially available plant-derived therapies for BPH. 26 Results shown for one drug, in terms of mechanism of action and clinical efficacy, are not applicable to alternative products and it is therefore not permissible to extrapolate the proven value of one drug to all.
The variation observed with plant-derived BPH drugs has been mirrored among commercially available herbal treatments for a variety of conditions. 27 In an analysis of the label description and actual content of 10 commonly purchased herbal preparations, including SrE, only 43% were found to have ingredient levels consistent with those listed. Pharmaceutical quality may also have a bearing on the bioavailability of active components of a given drug. 28 Comparison of two brands of Ginkgo biloba revealed marked differences in bioavailability among products due to variable dissolution rates. Such variation impacts the extent of drug absorption and probably efficacy levels as a result. Examining the evidence base of a particular drug may therefore be a means of ensuring its quality.
Permixon has been subjected to greater scrutiny and involved in more clinical trials than any other preparation of SrE. Its inhibitory action on dihydrotestosterone (DHT) formation from testosterone, its anti-inflammatory and anti-proliferative properties and its selectivity for the prostate have been documented, 13, 15, 16, [29] [30] [31] alongside evidence of its clinical efficacy in the improvement of urinary symptoms among BPH patients. [21] [22] [23] [24] [25] If the recommendations of the 5th International Consultation on BPH are considered, these results cannot be applied to alternative sources of SrE.
Large scale, well-designed clinical trials of alternative brands of SrE for the treatment of mild-to-moderate cases of symptomatic BPH are needed before the potential of these products may be defined in the same way as Permixon and before definitive comparisons can be made. 
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Awareness of the differences in content, and the variation between actual and stated doses among brands, may influence patient and doctor perception of the clinical efficacy of different products containing SrE. If use of one brand does not yield tangible clinical benefit, possibly due to minimal content of an active agent, this may lead to more reliable products being 'tarred with the same brush'. Clearly, these products vary significantly and increased recognition of individual brands, and their associated clinical profiles, is desirable. Greater awareness of the recommendations of the 5th International Consultation on BPH may lead to improved recognition of this issue.
Conclusion
The results of this comparative study indicate that sources of SrE vary significantly between brands. Elements considered to be active in the reduction of BPH-related LUTS are found in vastly different amounts.
The differences in content between the 14 brands analysed here is further evidence of the 5th International Consultation on BPH's recommendation that plantderived pharmaceuticals be analysed separately and considered as distinct entities. The potential benefits of such medication, with symptom improvement equal to that of synthetically derived drugs and a much improved side-effect profile, when accompanied by a complete range of successful large-scale clinical trials, are manifold.
Plant-derived medications are already likely to appeal to patients, however, full analysis and formal evaluation is needed to ensure that they will also be attractive to physicians. The combination of reproducible clinical efficacy with a high concentration of the active fraction is needed for all SrE preparations. In the absence of such proof, effective comparisons are impossible and the clinical benefit observed for one brand may not be extrapolated to others.
